INTS
Price
$2.31
Change
+$0.10 (+4.52%)
Updated
Mar 10, 04:49 PM (EDT)
Capitalization
34.89M
2 days until earnings call
SYRE
Price
$18.68
Change
-$0.81 (-4.16%)
Updated
Mar 10, 04:59 PM (EDT)
Capitalization
1.17B
58 days until earnings call
Ad is loading...

INTS vs SYRE

Header iconINTS vs SYRE Comparison
Open Charts INTS vs SYREBanner chart's image
Intensity Therapeutics
Price$2.31
Change+$0.10 (+4.52%)
Volume$100
Capitalization34.89M
Spyre Therapeutics
Price$18.68
Change-$0.81 (-4.16%)
Volume$9.78K
Capitalization1.17B
INTS vs SYRE Comparison Chart
Loading...
INTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INTS vs. SYRE commentary
Mar 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INTS is a Hold and SYRE is a Hold.

Ad is loading...
COMPARISON
Comparison
Mar 11, 2025
Stock price -- (INTS: $2.21 vs. SYRE: $19.49)
Brand notoriety: INTS and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INTS: 50% vs. SYRE: 189%
Market capitalization -- INTS: $34.89M vs. SYRE: $1.17B
INTS [@Biotechnology] is valued at $34.89M. SYRE’s [@Biotechnology] market capitalization is $1.17B. The market cap for tickers in the [@Biotechnology] industry ranges from $383.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INTS’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • INTS’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, both INTS and SYRE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INTS’s TA Score shows that 3 TA indicator(s) are bullish while SYRE’s TA Score has 4 bullish TA indicator(s).

  • INTS’s TA Score: 3 bullish, 5 bearish.
  • SYRE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than INTS.

Price Growth

INTS (@Biotechnology) experienced а -5.56% price change this week, while SYRE (@Biotechnology) price change was -1.07% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.84%. For the same industry, the average monthly price growth was -7.68%, and the average quarterly price growth was -7.37%.

Reported Earning Dates

INTS is expected to report earnings on May 08, 2025.

SYRE is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (+0.84% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($1.17B) has a higher market cap than INTS($34.9M). INTS YTD gains are higher at: 25.568 vs. SYRE (-16.280). INTS has higher annual earnings (EBITDA): -16.26M vs. SYRE (-195.07M). SYRE has more cash in the bank: 414M vs. INTS (2.78M). SYRE has less debt than INTS: SYRE (0) vs INTS (145K). INTS (0) and SYRE (0) have equivalent revenues.
INTSSYREINTS / SYRE
Capitalization34.9M1.17B3%
EBITDA-16.26M-195.07M8%
Gain YTD25.568-16.280-157%
P/E RatioN/A1.72-
Revenue00-
Total Cash2.78M414M1%
Total Debt145K0-
FUNDAMENTALS RATINGS
SYRE: Fundamental Ratings
SYRE
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
88
P/E GROWTH RATING
1..100
81
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
INTSSYRE
RSI
ODDS (%)
N/A
Bullish Trend 4 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
90%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
MACD
ODDS (%)
Bullish Trend 4 days ago
57%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
89%
Advances
ODDS (%)
Bullish Trend 11 days ago
63%
Bullish Trend 5 days ago
86%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 12 days ago
90%
BollingerBands
ODDS (%)
N/A
Bullish Trend 4 days ago
81%
Aroon
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
89%
View a ticker or compare two or three
Ad is loading...
INTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JNVSX18.870.30
+1.62%
Jensen Quality Mid Cap J
TRXAX11.800.07
+0.60%
Catalyst/MAP Global Balanced A
RCOCX43.980.26
+0.59%
Victory RS Large Cap Alpha C
IYITX22.67-0.04
-0.18%
Macquarie International Core Eq R
LGLAX42.44-0.30
-0.70%
Lord Abbett Growth Leaders A

INTS and

Correlation & Price change

A.I.dvisor tells us that INTS and CARA have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INTS and CARA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INTS
1D Price
Change %
INTS100%
-4.33%
CARA - INTS
30%
Poorly correlated
+1.65%
ACAD - INTS
28%
Poorly correlated
-0.28%
CCCC - INTS
27%
Poorly correlated
N/A
ADCT - INTS
25%
Poorly correlated
+5.14%
GPCR - INTS
25%
Poorly correlated
-3.87%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with APGE. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then APGE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
-4.93%
APGE - SYRE
50%
Loosely correlated
+1.98%
SNPX - SYRE
47%
Loosely correlated
+3.15%
PMN - SYRE
44%
Loosely correlated
+4.40%
ACLX - SYRE
43%
Loosely correlated
+3.12%
PRME - SYRE
42%
Loosely correlated
+4.35%
More